The launch emphasizes enabling regulated life sciences organizations to deploy AI safely, compliantly, and with auditable systems.

The AI Solutions cover the full lifecycle from concept and feasibility to deployment and post-market management, with regulatory strategy aligned to FDA, EU MDR/IVDR, and global guidelines.

Regulatory strategy is provided for AI- and ML-enabled products, including alignment with FDA Good Machine Learning Practice, EU MDR/IVDR, and global guidelines, and the lifecycle spans concept through post-market governance.

For more information, EMMA International provides contact details and social media channels, including a link to their AI Solutions page.

Contact information is provided for further details, featuring a Marketing Specialist and multiple social media channels for EMMA International.

Their offerings span intelligent automation across documentation and quality systems, manufacturing analytics, and clinical data review to reduce manual burden while enhancing compliance.

Key focus areas include AI validation, data integrity, bias monitoring, explainability, and lifecycle controls for continuously learning algorithms, with integration into quality systems and governance structures.

Key considerations addressed include data integrity, model performance, bias monitoring, explainability, and lifecycle controls for continuously learning algorithms.

EMMA International announces the launch of AI Solutions for the life sciences industry to enable safe and compliant AI adoption in regulated environments.

EMMA International unveils AI Solutions for the life sciences, offering governance, risk management, and training services that include governance framework design, policy development, post-market surveillance planning, and strategic AI road-mapping to align AI investments with business and regulatory priorities.

The firm emphasizes cross-disciplinary expertise in AI, regulatory affairs, quality systems, and data governance to support AI adoption in regulated environments across pharma, biotech, medical devices, diagnostics, and digital health.

The offerings address AI-driven process optimization across documentation, quality records, supplier oversight, manufacturing analytics, and clinical data review to reduce manual burden while strengthening compliance.